| Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates |
Entered into an agreement to be acquired by Novartis for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right ("CVR") upon the achievement of a regulatory milestone, for a total equity value of up to approximately $1.7 billion; Expected to be completed in the second half of 2025, subject to customary closing conditions Positive topline data from the completed fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) study of farabursen (RGLS8429) for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Company on track for initiation of Phase 3 single pivotal trial in the third quarter 2025 SAN DIEGO , May 8, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update. "We recently announced that we have entered into an agreement to be acquired by Novartis, whose established global development and commercial capabilities will potentially bring farabursen to patients with ADPKD, who currently have limited treatment options," said Jay Hagan, CEO of Regulus Therapeutics. |
prnewswire.com |
2025-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS |
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Regulus Therapeutics Inc. (NasdaqCM: RGLS) to Novartis AG. Under the terms of the proposed transaction, shareholders of Regulus will receive $7.00 per share in cash and a contingent value right providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect. |
businesswire.com |
2025-05-04 16:25:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Regulus Therapeutics Inc. - RGLS |
NEW YORK , April 30, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Regulus Therapeutics Inc. (NASDAQ: RGLS ), relating to the proposed merger with Novartis AG. |
prnewswire.com |
2025-04-30 18:10:00 |
Czytaj oryginał (ang.) |
| Crude Oil Falls Over 3%; Regulus Therapeutics Shares Spike Higher |
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling over 1% on Wednesday. |
benzinga.com |
2025-04-30 16:24:25 |
Czytaj oryginał (ang.) |
| Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million |
Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion. |
benzinga.com |
2025-04-30 15:22:41 |
Czytaj oryginał (ang.) |
| RGLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Regulus Therapeutics Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Regulus Therapeutics Inc. (NASDAQ: RGLS) to Novartis AG in cash is fair to Regulus shareholders. Under the terms of the proposed transaction, Regulus shareholders will receive $7.00 per share in cash and a contingent value right providing for payment of $7.00 per share, contingent upon the achievement of a milestone with respect to regulatory approval of Regulus' lead product candidate. |
businesswire.com |
2025-04-30 13:00:00 |
Czytaj oryginał (ang.) |
| Shareholder Alert: The Ademi Firm Investigates Whether Regulus Therapeutics Inc. Is Obtaining a Fair Price for Its Public Shareholders |
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Regulus (Nasdaq: RGLS) for possible breaches of fiduciary duty and other violations of law in its transaction with Novartis. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of Regulus will receive only $7.00 per share in cash at closing, or $0.8 billion. In addition. |
businesswire.com |
2025-04-30 11:41:00 |
Czytaj oryginał (ang.) |
| Novartis to buy Regulus Therapeutics for up to $1.7 billion |
Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday. |
reuters.com |
2025-04-30 11:25:03 |
Czytaj oryginał (ang.) |
| Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure |
Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage biopharmaceutical company focused on developing microRNA therapeutics. Regulus' lead asset, farabursen, is a potential first-in-class, next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The agreed deal is fully in line with the therapeutic area focus of Novartis and leverages our strength and expertise in renal disease. |
globenewswire.com |
2025-04-30 11:10:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Enters into Agreement to be Acquired by Novartis AG |
Novartis to acquire Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash through a contingent value right, for a total equity value of up to approximately $1.7 billion Transaction is expected to be completed in the second half of 2025, subject to customary closing conditions SAN DIEGO , April 30, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into an agreement and plan of merger with Novartis AG ("Novartis") and an indirectly wholly owned subsidiary of Novartis, pursuant to which Novartis will acquire Regulus for an initial payment of $7.00 per share in cash at closing, or $0.8 billion. The upfront cash portion of the consideration represents a premium of 274 percent to Regulus' 60-day volume-weighted average stock price and 108 percent to Regulus' closing price on April 29, 2025. |
prnewswire.com |
2025-04-30 11:00:00 |
Czytaj oryginał (ang.) |
| Should You Buy Regulus (RGLS) After Golden Cross? |
Regulus Therapeutics Inc. (RGLS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, RGLS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross. |
zacks.com |
2025-04-24 14:55:40 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics to Present at the 2025 Oppenheimer Innovation on the Island Biotech Summit |
SAN DIEGO , April 2, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that Jay Hagan, CEO, will participate in a presentation at the 2025 Oppenheimer Innovation on the Island Biotech Summit on Wednesday, April 9 th at 11:32 a.m. ET. The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date. |
prnewswire.com |
2025-04-02 12:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Stock Shoots Higher After Positive Results From Investigational Drug For Rare Type Of Kidney Disease |
Regulus Therapeutics Inc. RGLS released topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen (RGLS8429) autosomal dominant polycystic kidney disease (ADPKD) on Thursday. |
benzinga.com |
2025-03-27 14:59:04 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Positive Topline Data from the Fourth Cohort of Patients Consistent demonstration of polycystin (PC) biomarker impact confirming 300 mg fixed dose selection to achieve optimal kidney exposure Patients receiving 300 mg farabursen demonstrated a mean halting of height-adjusted total kidney volume (htTKV) growth over 4 months Exploratory analysis of patients from high-dose cohorts demonstrates statistical significance in htTKV change compared to a large cohort of historical placebo-treated patients, which meaningfully derisks the 12-month htTKV endpoint in the planned Phase 3 trial Company on track for initiation of Phase 3 single pivotal trial in third quarter 2025 SAN DIEGO , March 27, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from all patients in the fourth cohort in its Phase 1b MAD study of farabursen for the treatment of ADPKD. The Phase 1b MAD study is a double-blind, placebo-controlled trial which evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD) of farabursen in adult patients with ADPKD. |
prnewswire.com |
2025-03-27 09:00:00 |
Czytaj oryginał (ang.) |
| 4 Best Stocks To Buy Under $5 |
If you're one of the over 4 Million Americans set to retire this year, you may want to pay attention. |
247wallst.com |
2025-03-20 10:36:44 |
Czytaj oryginał (ang.) |
| What Makes Regulus (RGLS) a New Buy Stock |
Regulus (RGLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-03-19 15:06:13 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates |
Positive topline results from an interim analysis of the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of farabursen (RGLS8429) for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Agreement on key components of a Phase 3 single pivotal trial for potential Accelerated Approval with the U.S. Food and Drug Administration (FDA) SAN DIEGO , March 13, 2025 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update. |
prnewswire.com |
2025-03-13 18:05:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics to Present at the Leerink Partners 2025 Global Healthcare Conference |
SAN DIEGO , March 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will participate in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference on Tuesday, March 11 th at 3:40 p.m. ET. The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date. |
prnewswire.com |
2025-03-04 10:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
SAN DIEGO , Feb. 4, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11 th at 2:40 p.m. ET. The live event and replay of the presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date. |
prnewswire.com |
2025-02-04 10:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Announces Positive Clinical and Regulatory Updates from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program for Farabursen (RGLS8429) |
Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose response Exploratory results of imaging-based biomarkers continued to show reduction in height-adjusted total kidney volume (htTKV) growth rate Successful End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) with agreement on key components of a Phase 3 single pivotal trial for potential Accelerated Approval Company to hold conference call at 8:30 a.m. ET today SAN DIEGO , Jan. 29, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive clinical and regulatory updates from its ADPKD program. |
prnewswire.com |
2025-01-29 09:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Announces Participation at Upcoming Healthcare Investment Conferences |
SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: Evercore 7th Annual HealthCONx Conference: Fireside chat on Tuesday, December 3, 2024, at 3:50 p.m. ET Piper Sandler 36th Annual Healthcare Conference: Presentation on Wednesday, December 4, 2024, at 11:10 a.m. |
prnewswire.com |
2024-11-26 10:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Updates |
Completed enrollment in the fourth cohort of the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Presented a poster highlighting data from the ongoing MAD study of RGLS8429 in ADPKD at American Society of Nephrology (ASN) Kidney Week On track for an End-of-Phase 1 meeting by year-end Ended third quarter 2024 with cash, cash equivalents, and investments of $87.3 million; Cash runway into H1 2026 SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate update for the third quarter ended September 30, 2024. "We have remained focused on rapidly progressing RGLS8429 for the potential treatment of ADPKD and were pleased to announce the completion of enrollment in our fourth and final cohort of the Phase 1b MAD study last month. |
prnewswire.com |
2024-11-07 18:05:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Announces Completion of Enrollment in Fourth Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
SAN DIEGO , Oct. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment of 26 patients in the fourth cohort in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. "The completion of enrollment of our final cohort marks an important milestone as we near the end of our Phase 1b study. |
prnewswire.com |
2024-10-08 12:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences |
SAN DIEGO , Aug. 28, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: Wells Fargo Healthcare Conference: Fireside chat on Wednesday, September 4, 2024, at 2:15 p.m. ET H.C. Wainwright 26th Annual Global Investment Conference: Fireside chat on Monday, September 9, 2024, at 10:00 a.m. |
prnewswire.com |
2024-08-28 12:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates |
Announced positive topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 in autosomal dominant polycystic kidney disease (ADPKD) On track for an End-Of-Phase 1 meeting by year-end Appointed Rekha Garg, M.D., M.S., to Chief Medical Officer Ended second quarter 2024 with cash, cash equivalents, and investments of $95.9 million; Cash runway into H1 2026 SAN DIEGO , Aug. 8, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. |
prnewswire.com |
2024-08-08 20:05:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference |
SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that members of the management team will present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13 th at 8:30 a.m. ET. A replay of the live presentation will be available under "Events and Presentations" through the investor relations section of the Company's website at https://ir.regulusrx.com/events and archived for 90 days following the presentation date. |
prnewswire.com |
2024-08-06 12:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences |
SAN DIEGO , July 9, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that the Company will participate in the following investor conferences: H.C. Wainwright Third Annual Kidney Virtual Conference: Fireside chat on Monday, July 15, 2024, at 10:30 a.m. |
prnewswire.com |
2024-07-09 12:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Continued mechanistic dose response observed following completion of 3 mg/kg dose level based on urinary biomarker analyses Percent change from baseline in PC1 and PC2 demonstrated a dose response across all doses tested, with statistical significance seen at 3 mg/kg compared to placebo Exploratory imaging analyses indicated reduction in total kidney volume in 70% of patients dosed with 3 mg/kg Fourth cohort enrollment underway Company to hold conference call at 8:30am ET today SAN DIEGO , June 24, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the third cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. The Phase 1b MAD study is a double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD) of RGLS8429 in adult patients with ADPKD. |
prnewswire.com |
2024-06-24 11:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes |
SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it expects to be added to the broad-market Russell 3000® Index and the Russell 2000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th, ranking them by total market capitalization. |
prnewswire.com |
2024-06-04 12:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer |
SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer effective May 16, 2024. |
prnewswire.com |
2024-05-16 12:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates |
Initiated the fourth cohort of patients in the Phase 1b multiple-ascending dose (MAD) clinical trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD) Topline data from the third cohort of patients in the Phase 1b MAD study of RGLS8429 expected in mid-2024 Ended first quarter 2024 with cash, cash equivalents, and investments of $107.7 million; Cash runway into H1 2026 SAN DIEGO , May 9, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. "Our work in ADPKD continues to progress and most recently we announced the initiation of our fourth, and final, cohort in the Phase 1b MAD study of RGLS8429," said Jay Hagan, CEO of Regulus. |
prnewswire.com |
2024-05-09 20:05:00 |
Czytaj oryginał (ang.) |
| The $5 Phenoms: 3 Cheap Stocks That Could Skyrocket by 2028 |
Finding good investment opportunities in the constantly changing stock market is similar to uncovering hidden treasures. Certain cheap stocks to buy are particularly noteworthy because they can yield significant gains. |
investorplace.com |
2024-05-07 10:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
SAN DIEGO , May 6, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced, after review of all available safety data, the Company initiated screening in the of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the fourth cohort will receive an open label fixed dose of 300 mg of RGLS8429 every other week for three months. |
prnewswire.com |
2024-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series |
SAN DIEGO , April 30, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that CEO Jay Hagan and President & Head of Research & Development Preston Klassen, M.D., will be participating in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series hosted by Whitney Ijem on Wednesday, May 1, 2024, at 1:00 p.m. |
prnewswire.com |
2024-04-30 12:00:00 |
Czytaj oryginał (ang.) |
| Regulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKD |
Regulus Therapeutics Inc. achieved positive results in cohort 2 of phase 1b study, using RGLS8429 for patients with autosomal polycystic kidney disease; Improvement of PC1 & PC2 proteins and reduction of cysts. Additional results from cohort 3 of phase 1b study, using RGLS8429 for patients with ADPKD, expected in mid-2024; Higher dose of 3 mg/kg of drug being deployed for this cohort. Highly positive Type D meeting held with FDA and stated that a single phase 2 study could be used for an Accelerated Approval of RGLS8429 for ADPKD. |
seekingalpha.com |
2024-04-10 16:51:42 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates |
Positive topline data from the second cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Oversubscribed $100 million private placement; expected to extend cash runway into H1 2026 Completed enrollment of the third cohort of patients in the MAD study; Data anticipated mid-2024 Completed Type D Meeting with FDA to Discuss Pathway for Accelerated Approval of RGLS8429 SAN DIEGO, March 21, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update. "2023 was a productive year for Regulus, and the growing momentum in our Phase 1b MAD study of RGLS8429 is further emphasized by our announcement of key milestones and data readouts, including the recent positive topline data from the second cohort of patients. |
prnewswire.com |
2024-03-21 18:05:00 |
Czytaj oryginał (ang.) |
| Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study |
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease. |
zacks.com |
2024-03-13 15:11:11 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity |
SAN DIEGO , March 12, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors. The oversubscribed financing includes participation from new and existing institutional investors, including Adage Capital Partners L.P. |
prnewswire.com |
2024-03-12 08:32:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney volume seen in patients with the highest increases in PC1 and PC2 Cohort 3 fully enrolled with data readout anticipated in mid-2024; Cohort 4 screening to start in 2Q 2024 Company to hold conference call at 8:30am ET today SAN DIEGO , March 12, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced positive topline results from the second cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. The Phase 1b MAD study is a double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD) of RGLS8429 in adult patients with ADPKD. |
prnewswire.com |
2024-03-12 08:30:00 |
Czytaj oryginał (ang.) |
| Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) |
SAN DIEGO , Jan. 2, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced it has completed enrollment in the third cohort of patients in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD. "The completion of our third and final randomized placebo-controlled cohort in the Phase 1b MAD study is an exciting step for Regulus, and we are happy to reach this stage of development for RGLS8429," said Jay Hagan, CEO of Regulus. |
prnewswire.com |
2024-01-02 18:05:00 |
Czytaj oryginał (ang.) |